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Abstract 51 
Angiogenesis contributes in multiple ways to disease progression in tumors and reduces 52 
treatment efficiency. Molecular therapies targeting Vegf signaling combined with 53 
chemotherapy or other drugs exhibit promising results to improve efficacy of treatment. 54 
Dopamine has been recently proposed to be a novel safe antiangiogenic drug that stabilizes 55 
abnormal blood vessels and increases therapeutic efficacy. Here, we aimed to identify a 56 
treatment to normalize tumoral vessels and restore normal blood perfusion in tumor tissue 57 
with a Vegf receptor inhibitor and/or a ligand of dopamine G protein-coupled receptor D2 58 
(D2R). Dopamine, via its action on D2R, is an endogenous effector of the pituitary gland, and 59 
we took advantage of this system to address this question. We have used a previously 60 
described Hmga2/T mouse model developing haemorrhagic prolactin-secreting adenomas. In 61 
mutant mice, blood vessels are profoundly altered in tumors, and an aberrant arterial 62 
vascularization develops leading to the loss of dopamine supply. D2R agonist treatment 63 
blocks tumor growth, induces regression of the aberrant blood supply and normalizes blood 64 
vessels. A chronic treatment is able to restore the altered balance between pro- and anti-65 
angiogenic factors. Remarkably, an acute treatment induces an up-regulation of the stabilizing 66 
factor Angiopoietin 1. An anti-Vegf therapy is also effective to restrain tumor growth and 67 
improves vascular remodeling. Importantly, only the combination treatment suppresses 68 
intratumoral hemorrhage and restores blood vessel perfusion, suggesting that it might 69 
represent an attractive therapy targeting tumor vasculature. Similar strategies targeting other 70 
ligands of GPCRs involved in angiogenesis may identify novel therapeutic opportunities for 71 
cancer.  72  73  74  75 
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Introduction 76 
Pathological angiogenesis, generated by an imbalance of pro- and antiangiogenic 77 
factors, provides oxygen and nutrients to tumors, and is a hallmark of many benign and 78 
malignant diseases 1, 2. New blood vessels within tumors are impaired in their function and 79 
structure, and this abnormal vascular network causes alterations in blood flow and 80 
oxygenation that can further increase tumor growth and alter the anti-tumor efficiency of 81 
cytotoxic drugs 3, 4. Results from clinical trials using anti-Vegf agents have revealed that 82 
efficacy of anti-angiogenic monotherapy can be inadequate in term of response or survival 83 
rates 5. To improve treatment efficiency, novel combinations of anti-Vegf therapy with 84 
chemotherapy or radiation have been developed, with promising results 5, 6. Thus, a recent 85 
study performed by Jain's group investigating a combination treatment with anti-Vegf and 86 
chemotherapy, showed that early vessel normalization improves tumor perfusion and survival 87 
in a subset of glioblastoma patients 7. Of interest, another option is to combine Vegf-signaling 88 
inhibitors with antiangiogenic agents targeting alternative pathways. In this regard, the use of 89 
inhibitors targeting Vegf and Angiopoietin 2 has shown complementary actions on tumor 90 
growth and angiogenesis 8, 9.  91 
Alternative strategies for normalizing vessels and blood flow in tumoral tissues are 92 
based on the use of ligands for G protein-coupled receptors (GPCRs) 10. Among the recently 93 
discovered candidates, D2 receptors and their natural ligand dopamine (DA) are of particular 94 
interest as, in addition to its major role as a neurotransmitter within the brain, DA controls 95 
vascular tone and blocks Vegf-dependent increase in vascular permeability 11, 12. DA 96 
influences tumor behavior as well, especially by controlling cell proliferation and processes 97 
leading to angiogenesis 13, 14. DA is not only an anti-tumoral and anti-angiogenic drug, it also 98 
normalizes abnormal tumor blood vessels by acting on pericytes and endothelial cells, and 99 
therefore improves tumor perfusion by increasing blood flow, decreasing hypoxia and 100 
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enhancing the concentration of anti-cancer drug in tissue 15. A recent study showed that DA 101 
therapy also prevents 5-fluoracil mediated neutropenia 16. Hence, DA has been proposed to be 102 
a novel therapy for the treatment of cancer and chemotherapy-induced disorders 15-17. 103 
In this context, we examined whether an anti-Vegf therapy combined with D2 receptor 104 
ligands could exert additive effects to normalize blood vessels in tumors. We tested this 105 
hypothesis on the pituitary gland since DA is also an endogenous effector of this master gland 106 
and plays a central role in tonically inhibiting prolactin (PRL) release via D2 receptors located 107 
on lactotrophs 18. Blood perfuses the normal pituitary via incoming vessels from the pituitary 108 
portal circulation at the base of the brain. Previous studies have reported that prolactinomas in 109 
rats 19 and in humans 20 are associated with the development of a direct arterial blood supply, 110 
which may lead in turn to an escape from inhibitory hypothalamic regulation since systemic 111 
blood contains very low DA levels in comparison with portal blood. Prolactinomas are in 112 
general treated by medical therapy with DA agonists, and an anti-angiogenic strategy using 113 
anti-Vegf agents has been recently proposed to treat aggressive human pituitary tumors 21. 114 
These tumors are therefore an excellent model for investigation of the use of DA and Vegf for 115 
tumor therapy through modification of vascular defects. 116 
We have used the Hmga2/T mouse model, which develops PRL-secreting adenomas 22 117 
and has been previously used to test the efficacy of new drugs for the therapy of human 118 
pituitary tumors 23, to investigate the status of endogenous DA during tumoral development 119 
and the effects of a D2R agonist on tumor growth and vasculature. Moreover, we have 120 
examined whether DA and anti-Vegf agent could exert complementary effects on structural 121 
and functional properties of tumoral blood vessels. We show that a loss in endogenous DA 122 
inhibitory tone is concomitant with tumor progression and is associated with aberrant growth 123 
of blood vessels. D2R agonist treatment inhibits tumor growth and normalizes abnormal 124 
blood vessels. Molecular mechanisms induced by D2R agonist are able to reverse the 125 
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profound alterations of the angiogenic profile in tumoral glands and involve an up-regulation 126 
of the stabilizing factor Angiopoietin1. Strikingly, although anti-Vegf treatment is also able to 127 
normalize tumoral blood vessels and prevents tumor growth, only the combination treatment 128 
suppresses intratumoral hemorrhage and restores blood vessel perfusion. 129 
 130 
Materials and Methods 131 
Mouse model 132 
All animal studies complied with the animal welfare guidelines of the European 133 
Community. They were approved by the Direction of Veterinary departments of Herault and 134 
the Languedoc Roussillon Institutional Animal Care and Use Committee (#CEEA-LR-135 
12119). Animals were housed in light (12-hour light, 12-hour dark cycle) and temperature 136 
(22-24°C) controlled rooms and fed a normal diet with free access to tap water. 137 
Experiments were performed on mixed 129/SVJ x C57BL/6 female mice, either wild-138 
type (WT) or overexpressing ubiquitously a truncated form of Hmga2 protein 24 (Hmga2/T 139 
mice). In this model, pituitaries from females exhibited an extended period of hyperplasia, 140 
starting around 3 months of age, followed by tumor onset between 9 to 11 months 141 
(Supporting Information Fig. 1). These tumors appeared very hemorrhagic and 142 
immunohistochemical experiments showed that they were prolactinomas. A strong correlation 143 
was observed between circulating PRL levels and tumor weight (R2 = 0.936), as reported in 144 
human prolactinomas 25, 26. We thus decided to monitor hormone output for each mouse once 145 
a week to follow tumor initiation and progression. Unless otherwise specified, the majority of 146 
experiments were performed on cohorts of mice with circulating PRL concentrations between 147 
400 and 800 ng/ml and corresponding to tumors of 13-18 mg.  148 
 149 
ELISA assay for PRL 150 
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Blood levels of PRL were measured using an ultra-sensitive ELISA method recently 151 
established in the laboratory 27. Briefly, whole blood (4 µl) was collected from the tail vein of 152 
conscious mice, immediately diluted (1/30) in PBS-T (PBS, 0.05% Tween20), and then 153 
frozen at –20°C until use.  154 
 155 
Injection or administration of drugs in mice 156 
The dopaminergic inhibitory tone was evaluated by an intraperitoneal (ip) injection of 157 
the D2R antagonist domperidone (20 mg/kg, Abcam) and measurement of circulating PRL 3 158 
times before (basal) and then 30 min and 45 min after the injection. The DA inhibitory tone 159 
was determined by the maximum fold increase in PRL blood levels and corresponds to the 160 
ratio between the maximum secretion and the basal level (mean of PRL blood concentration 161 
of the 3 points preceding domperidone injection).  162 
Bromocriptine mesylate implants (60 days, 10 mg pellet, Innovative Research of 163 
America) were placed under the skin of the neck of Hmga2/T mice harboring pituitary 164 
tumors, for 6 weeks. Some mice received ip injections of bromocriptine (6 mg/kg, Sigma-165 
Aldrich) twice a day over the course of 48 h. 166 
Axitinib (20 mg/kg, Abmole Bioscience Inc.) or sucralose were given to the mice by 167 
voluntary oral administration, twice a day for 6 weeks, after training of the mice 168 
(http://www.nature.com/protocolexchange/protocols/2099).  169 
 170 
Immunohistochemistry  171 
Immunohistochemical analyses were performed as previously reported 28. Briefly, 172 
pituitary tissue sections from WT and Hmga2/T mice with and without various treatments 173 
were prepared with a vibratome and then stained with a sheep polyclonal tyrosine 174 
hydroxylase antibody (TH, 1:1000, Ab113, Abcam), with a rabbit polyclonal phosphorylated 175 
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TH antibody (pTH, 1:1000, AB5423, Milipore), or with a rat monoclonal endomucin antibody 176 
(1:500, sc-53941, Santa Cruz) as a marker for pituitary endothelial cells. In one set of 177 
experiments, pituitary paraffin sections were stained with a rat monoclonal endomucin 178 
antibody (1:500, sc-53941, Santa Cruz). Sections were observed with an epifluorescence 179 
(Carl-Zeiss Axio Imager Z1) or a confocal microscope (LSM510 Zeiss). Four parameters 180 
were evaluated using ImageJ software to characterize quantitatively pituitary 181 
microvasculature: the mean vessel area, the microvessel density, the total vessel area and the 182 
area of extravasation of red blood cells. Detailed protocol is presented in Supporting 183 
Information Material and Method section. 184 
 185 
Scanning and Transmission Electron Microscopy  186 
Ultrastructural analyses were performed as previously described 29, in WT and 187 
Hmga2/T mice receiving or not different treatments. Different parameters characterizing 188 
blood vessel structure observed by Transmission Electron Microscopy (TEM) were quantified 189 
using ImageJ software: the perimeter of the lumen, the circularity (a value of 1 indicates a 190 
perfect circle) and the solidity (defined as the ratio of an object area/area of the convex hull of 191 
the object, objects with irregular shapes have a solidity value approaching 0), reflecting the 192 
tortuosity of the vessels.  193 
 194 
Injection of microspheres in the general circulation 195 
To assess vascular supply in pituitary adenomas, fluorescent microsphere were 196 
injected in the circulation following a previously described protocol 19. Minor modifications 197 
are presented in Supporting Information Material and Methods section. 198 
 199 
In vivo amperometry  200 
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 A detailed protocol of in vivo amperometry is given in Supporting Information 201 
Material and Methods section. Briefly, after anaesthesia with ketamine-xylazine, mice were 202 
fixed on a stereotactic frame, and a carbon fiber microelectrode was inserted in a support 203 
guide cannula, with its tip reaching the median eminence at stereotaxic coordinates -1.3 mm 204 
rostro-caudal; 0 mm medio-lateral; 6.1 mm ventral. After at least one week of recovery, mice 205 
were transferred to the recording cages and connected to an electrical swivel to enable free 206 
movement. The microelectrodes were maintained at 700 mV to detect secretion of DA, and 207 
oxidation currents were recorded at 1 kHz. 208 
 209 
In vivo imaging of pituitary gland 210 
Cellular in vivo imaging of the pituitary gland allows determination of microvascular 211 
organisation and blood flow in the same region of the gland, and a detailed protocol has been 212 
previously reported 30. Injections of 150 kDa FITC-labeled dextran (Sigma-Aldrich) were 213 
performed via the jugular vein in WT and Hmga2/T mice. Fluorescence emission was 214 
captured by an EM-CCD camera 512 x 512 C9100 (Hamamatsu) and acquired with 215 
MetaMorph software (Molecular Devices). 216 
 217 
Blood vessel perfusion  218 
WT or Hmga2/T mice were anesthetized by inhalation of isoflurane (1.5% in O2) and 219 
a catheter was inserted in the jugular vein. Perfusion of blood vessels was evaluated after an 220 
intravenous injection of 1 mg of fluorescent 500 kDa dextran (dextran fluorescein, lysine 221 
fixable, Molecular Probes). After circulation for 15 min, a thoracic lethal dose of 222 
pentobarbital was administrated to the mice and pituitaries were fixed in 4% PFA. Tissue 223 
sections were prepared using a vibratome, and blood vessels were immunostained using an 224 
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endomucin antibody. Volocity software was used to measure overlap coefficient (M1) 225 
according to Manders et al. 31 reflecting the portion of blood vessels filled with dextran. 226 
 227 
Real-time RT-PCR 228 
Adenohypophysis were dissected from terminally anaesthetized mice. Total RNA was 229 
extracted and then reverse-transcribed as previously described 28, 32. Specific primers for qRT-230 
PCR were designed using the Primer Express 3.0 software, the sequences are shown in 231 
Supporting Information Table 1. PCR reactions are presented in Supporting Information 232 
Material and Method section. 233 
 234 
Statistics 235 
 Values represent mean ± SEM. Statistical tests were performed with Prism (GraphPad 236 
software). Normality was assessed using D'Agostino-Pearson test. Non-parametric statistical 237 
tests were used for some data sets, as indicated in figure legends. Multiple comparisons tests 238 
were selected when the number of data sets were >2. Statistical difference between groups 239 
was assumed when P<0.05. 240 
 241 
Results 242 
Aberrant blood supply leads to loss of dopaminergic inhibitory tone, associated with 243 
tumor progression 244 
We first characterized the vascular network in pituitary tumors by 245 
immunohistochemistry, scanning electron microscopy (SEM) and TEM (Fig. 1). The results 246 
demonstrate remodeling of the microvasculature in the tumors and structural abnormalities. 247 
The vascular density was decreased in tumors compared to WT, and tumoral blood vessels 248 
were dilated, tortuous and structurally altered (Fig. 1A and B) since blood lakes were present 249 
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(Fig. 1B and J). Changes in the organization of the vascular architecture in tumors were also 250 
confirmed at the ultrastructural level (Fig. 1 C to J). The endothelium of the blood vessels was 251 
irregular, discontinuous and damaged, presenting numerous protrusions into the lumen of the 252 
vessels, as described for other tumor types 33.  253 
To test whether tumorigenesis in our model was associated with the development of a 254 
direct arterial blood supply, we injected in the systemic circulation fluorescent microspheres 255 
with a diameter which is too large to pass through the primary portal capillaries in the median 256 
eminence (Supporting Information Fig. 2). Whilst in WT animals microspheres were 257 
restricted to the median eminence (Supporting Information Fig. 2A and B), in mice harboring 258 
tumors microspheres were also localized in the tumoral region (Supporting Information Fig. 259 
2C and D). The development of such an aberrant growth of blood vessels in tumors was 260 
directly visualized by in vivo imaging of the pituitary after an intravenous injection of 261 
fluorescent dextran. In WT mice (Fig. 1K), as expected, blood flow arrived from the median 262 
eminence through the portal system, and filled capillaries from the entire gland in a rostro-263 
caudal direction in less than 30 s. Although arteries from meninges surrounding pituitary were 264 
rapidly filled (t = 2 s), they never branched with the adenohypophysis blood vessels. By 265 
contrast, in Hmga2/T mice with a tumor beginning to develop (Fig. 1L), the blood flow from 266 
the portal system in the hyperplastic area was strongly slowed, while the tumoral region was 267 
perfused by vessels derived from dural arteries (Fig. 1L, arrow heads).  268 
The development of this aberrant direct vascularization induced a loss of endogenous 269 
DA inhibitory tone, although DA was still produced and released by tuberoinfundibular 270 
dopamine (TIDA) neurons (Fig. 2). By determining circulating PRL after an injection of a 271 
D2R antagonist, domperidone, in WT and hyperplastic glands, we found that the endogenous 272 
DA inhibitory tone was high (Fig. 2A). By contrast, it was decreased in 7-20 mg tumors, and 273 
very low, albeit still present, in tumors ≥ 20 mg. In addition, phosphorylated tyrosine 274 
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hydroxylase (the key enzyme involved in DA synthesis) was still present in neurons from the 275 
arcuate nucleus from Hmga2/T mice with pituitary tumors (Fig. 2B), suggesting that DA was 276 
produced in TIDA neurons. Accordingly, DA was released in vivo by TIDA neurons in the 277 
median eminence where it normally diffuses into the capillaries of the pituitary portal blood 278 
vessels. We performed in vivo amperometric measurements of DA secretion (Fig. 2C). 279 
Episodic secretion of DA was still detectable in animals with pituitary tumors, and did not 280 
appear grossly different from that in WT animals (Nicola Romanò, personal communication). 281 
Furthermore, the frequency of amperometric events did not decrease during tumor 282 
development (Fig 2C).  283 
Overall, these findings show that establishment of an aberrant blood supply leads to the 284 
loss in DA inhibitory tone, secondary to tumor onset, without major hypothalamic 285 
dysfunction.  286 
 287 
D2R agonist blocks aberrant blood supply, tumor progression and restores angiogenic 288 
balance 289 
To evaluate the impact of restoring DA on blood supply, we treated mice harboring 290 
pituitary tumors (Tumors t0), with subcutaneous implants of a D2R agonist bromocriptine for 291 
6 weeks (Bromocriptine 6 wks), and then analyzed the presence of the aberrant growth of 292 
blood vessels (Fig. 3). Of note, bromocriptine was able to inhibit PRL secretion: 24 hours 293 
after the implantation circulating PRL concentrations were low and remained controlled until 294 
sacrifice (< 50 ng/ml, data not shown), indicating that the Hmga2/T model had the ability to 295 
respond to bromocriptine treatment. This treatment totally blocked tumoral growth compared 296 
to untreated tumors (Tumors 6 wks, Fig. 3B). Pituitary weight was similar to that measured in 297 
Tumors t0 (Fig. 3B), and pituitaries appeared less hemorrhagic (Fig. 3A). Strikingly, 298 
bromocriptine treatment inhibited the progression of the aberrant vascularization as revealed 299 
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by a drastic decrease in the number of microspheres in pituitaries from bromocriptine-treated 300 
animals compared to untreated mice (Fig. 3C). The 5-fold decrease in the number of 301 
microspheres quantified between Tumors t0 and bromocriptine-treated tumors suggests that 302 
the D2R agonist induced a partial regression of the pre-existing aberrant vascularization. 303 
Immunostaining for D2R showed that D2R was present as expected in lactotrophs, but it was 304 
also detected in pituitary blood vessels (Supporting Information Fig. 3), suggesting that DA 305 
could exert its effects directly on blood vessels.   306 
We then investigated whether this chronic D2R agonist treatment could affect the 307 
expression of a panel of pro- and anti-angiogenic factors. Fig. 3D shows that the angiogenic 308 
profile, assessed by qPCR, was affected in tumors: angiogenic factor expression was up- or 309 
down-regulated, whilst during the period of hyperplasia, modulations were modest 310 
(Supporting Information Fig. 4A). Interestingly, bromocriptine treatment for 6 weeks was 311 
able to reverse these alterations (Fig. 3E) and restored an angiogenic signature close to that 312 
observed during hyperplasia (Supporting Information Fig. 4B).  313 
We next assessed the kinetics of bromocripine action on the angiogenic gene expression 314 
profile. After 2 days of treatment, among the set of genes studied, only 2 were rapidly 315 
regulated by bromocriptine (Fig. 3F; Supporting Information Fig. 4C): angiopoietin 1 316 
(Angpt1) and Prok1 (also named EG-Vegf) an angiogenic mitogen specific to endocrine 317 
glands 34. The mRNA levels for Angpt1 were low in tumors and an acute bromocriptine 318 
treatment restored its expression totally since the mRNA levels were similar to that found in 319 
WT animals (relative expression for Angpt1: 2.37 ± 0.32 in WT vs 2.41 ± 0.47 in 320 
bromocriptine-treated mice). Prok1 expression was partially restored by an acute 321 
bromocriptine treatment: relative expression for Prok1 was 1.68 ± 0.13 and 0.98 ± 0.46 in 322 
WT and bromocriptine-treated mice, respectively. Vegfa expression was not affected by 323 
bromocriptine treatment. Altogether, these results show that the D2R agonist blocked tumor 324 
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growth, induced regression of the aberrant vascularization and up-regulated the expression of 325 
Angpt1 and Prok1. 326 
 327 
Vegf contributes both to aberrant blood supply and tumoral growth 328 
Vegf has been shown to be involved in normal and tumoral vascular remodeling 5, 35 and 329 
has been reported to contribute to pituitary tumor progression in a murine model 36. We 330 
investigated whether Vegf could participate in the occurrence and development of the 331 
aberrant vascularization in tumors. We first established that aberrant direct vascularization 332 
starts to develop in mice with circulating PRL between 75 and 100 ng/ml (data not shown). 333 
We treated mice exhibiting such concentrations of PRL for 6 weeks with axitinib, a potent 334 
inhibitor of tyrosine kinase and selective from VegfR 37. Axitinib-treated tumors appeared 335 
less hemorrhagic than control tumors (Fig. 4A) and the antiangiogenic agent partially blocked 336 
tumor progression (Fig. 4B). The number of microspheres quantified in axitinib-treated 337 
tumors was significantly lower than in those of controls, demonstrating that Vegf contributes 338 
to the establishment of the aberrant blood supply in tumors (Fig. 4C). The effects of axitinib 339 
on expression of pro- and anti-angiogenic factors (Fig. 4D) showed that the angiogenic gene 340 
profile was differentially affected by axitinib compared to bromocriptine treatment (Fig. 3E), 341 
although some genes were regulated in a similar way by both treatments such as Rgs5 and 342 
Cspg4 for example. Importantly, the expression of Angpt1 and Prok1, which was up-regulated 343 
in response to bromocriptine treatment, was unchanged and remained low after axitinib 344 
treatment (Fig. 4D). These results suggest that D2R agonist treatment and anti-Vegf therapy 345 
could involve common as well as independent effects on angiogenic pathways.  346 
 347 
Bromocriptine or axitinib correct the structural abnormalities of tumoral vessels while 348 
the combination treatment restores blood vessel perfusion 349 
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We further addressed the complementary effects of D2R agonist and anti-Vegf therapy 350 
on blood vessel normalization (Fig. 5 and Supporting Information Fig. 5). Figure 5A shows 351 
that the combination treatment greatly reduced intratumoral hemorrhage. Analysis of pituitary 352 
vasculature in various conditions and morphometric measurements of blood vessels 353 
demonstrate that D2R agonist or axitinib had an equivalent capacity to improve structural 354 
defects present in tumoral blood vessels and that the combination treatment did not lead to a 355 
significant advantage (Fig. 5B and C and Supporting Information Fig. 5). Whilst vascular 356 
density was maintained in presence of D2R agonist treatment compared to untreated-tumors, 357 
axitinib notably decreased vascular density. In addition, blood vessel dilatation and tortuosity 358 
were improved by the different treatments (Supporting Information Fig. 5).  359 
Leakiness of tumoral blood vessels is of particular functional significance and 360 
intratumoral hemorrhage constitutes an indicator of this leakiness 33. Importantly, the 361 
combination treatment dramatically reduced leakiness of blood vessels (Fig. 5D). 362 
Quantification of the area of extravasation in various conditions showed that intratumoral 363 
hemorrhage in tumors represented more than 7% of the total surface area. Although it was 364 
significantly reduced by both bromocriptine or axitinib, only the combination treatment was 365 
able to prevent vessel leakiness since intratumoral hemorrhage was almost absent in 366 
bromocriptine + axitinib-treated tumors.  367 
Because of the highly disorganized epithelium lining endothelial cells, blood vessel 368 
perfusion is severely impaired in tumors 38. We assessed whether the positive effects of the 369 
combination treatment also included an improved vessel perfusion (Fig. 6). The portion of 370 
blood vessels filled with FITC-dextran was significantly decreased in tumors compared to 371 
WT (Fig. 6A and B), indicating that perfusion within the tumors was strongly affected and 372 
inappropriate. Bromocriptine- and axitinib-treatment improved partially vessel perfusion, and 373 
the combination treatment restored this almost entirely. Together, these results show that, 374 
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whilst bromocriptine and/or axitinib were able to correct structural abnormalities of tumoral 375 
vessels with a similar efficacy, only the combination treatment restored their function. 376 
 377 
Discussion 378 
We report here that a combination of D2R agonist treatment with anti-Vegf therapy 379 
specifically suppresses intratumoral hemorrhage and restores the perfusion of blood vessels. 380 
PRL-secreting pituitary adenomas undergo profound vascular remodeling along with 381 
formation of an aberrant arterial blood supply resulting in an escape from inhibitory 382 
hypothalamic regulation by DA. D2R agonist treatment blocks tumor growth and remarkably 383 
ameliorates abnormal blood vessel function. In addition, the altered balance between pro- and 384 
anti-angiogenic factors in tumors is restored by D2R agonist administration. An anti-Vegf 385 
therapy is also able to inhibit tumor growth and improves vascular remodeling. Furthermore, 386 
we show for the first time that a combination of anti-Vegf and GPCR ligand therapy exerts 387 
complementary effects on tumoral blood vessel normalization. 388 
Dual effects of dopamine on angiogenesis process. We show, in accordance with 389 
previous studies 35, 36, that anti-Vegf therapy induced a drastic reduction in vascular density. 390 
This anti-angiogenic effect was effective both on capillaries of the portal system and the 391 
extra-portal aberrant vascularization. By contrast, D2R agonist effects specifically induced the 392 
regression of the extra-portal aberrant vascularization. These antiangiogenic effects might be 393 
mediated in part via DA action on Vegf signaling 11, 39, 40. Notably, both treatments strongly 394 
down-regulated the angiogenic factor Rgs5, whose expression is closely associated with 395 
tumor-induced neovascularization and drastically reduced in vessels normalized under 396 
therapy 41. Despite the regression of this extra-portal blood system, the maintenance of the 397 
vascular density in D2R agonist-treated tumors may be due to the formation of de novo 398 
capillaries derived from the portal system, suggesting that DA could exert dual effects on 399 
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vascularization. Endothelial cells display a strong heterogeneity in terms of structure, function 400 
or gene expression 42. It is now well established that in tumors endothelial cells show multiple 401 
phenotypes that can vary during tumor progression and are mainly determined by the 402 
microenvironment 43. It is possible that D2R agonists act on both the extraportal and the portal 403 
blood system by distinct mechanisms, and these effects are probably mediated via different 404 
combinations of effectors. In this respect, Prok1 (also named EG-Vegf) is an interesting 405 
candidate to mediate specific DA actions. In humans, Prok1 has been shown to have a highly 406 
tissue-specific pattern of expression, and was proposed to be a mitogen that could regulate 407 
tissue-specific proliferation and differentiation of endothelial cells 34, in particular in 408 
endocrine glands. We show that its expression is down-regulated in prolactinomas and rapidly 409 
restored by D2R agonist treatment. Thus, this angiogenic factor could play a role in DA-410 
induced vasculature remodeling, especially in the formation of de novo blood vessels from the 411 
portal system. 412 
Vascular normalization by D2R agonist and Vegf inhibition. Although anti-Vegf 413 
specific monotherapy may not be as effective as initially expected in term of response and 414 
increase survival in patients with cancers, its combination with modulation of other signaling 415 
pathways may have promise 5, 6. We show that anti-Vegf and D2R agonist treatments given 416 
alone displayed partial and similar efficiency on blood vessel perfusion and intratumoral 417 
hemorrhage. Remarkably, D2R agonist and blockade of Vegf together had additive effects on 418 
vascular perfusion and leakage, suggesting complementary modes of action. This is supported 419 
by analysis of angiogenic factors rapidly regulated by DA, which highlighted Angpt1 as a 420 
putative candidate normalizing blood vessels. Up-regulation of Angpt1 was also maintained 421 
during long term D2R agonist treatment, while after anti-Vegf monotherapy Angpt1 levels 422 
remained low. Angpt1 and 2 are ligands of the vascular endothelial Tie2 receptor and bind to 423 
Tie2 with similar affinities, however they behave as mutual antagonists 44. Therefore, the 424 
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balance of Angpt1 and Angpt2 is critical for control of vascular normalization or angiogenesis 425 
via the same Tie2 receptor 45. Of note, in the present study, the Angpt1/Angpt2 ratio was 426 
decreased in tumors, and this ratio was reversed with the administration of D2R agonists. 427 
Vegf and Angpt1 exert antagonist effects on endothelial barrier function since Vegf increases 428 
vascular permeability, an effect which is inhibited by Angpt1, which also promotes blood 429 
vessels stabilization 44. Recent studies show that targeted Angpt1 monotherapy in pathological 430 
conditions is highly effective to suppress vascular leakage 46, 47. Moreover, DA-normalization 431 
of blood vessels in murine orthotopic models of colon and prostate cancers involved up-432 
regulation of Angpt1 15. We show here that DA effects on Vegf signaling is not sufficient to 433 
abrogate vascular leakage and concomitant Vegf blockade is required to totally suppress 434 
intratumoral hemorrhage. 435 
In summary, the present study demonstrates that D2R agonist and anti-Vegf therapy 436 
exert complementary actions on tumoral vessel normalization. This combinatorial approach 437 
might constitute an interesting option in treatment of prolactinomas, especially in cases where 438 
current therapy is ineffective or poorly tolerated. We anticipate that the novel combination 439 
treatment proposed in the present study could treat different tumor types in which DA exerts 440 
anti-angiogenic effects or normalizes tumoral blood vessels, such as ovarian carcinoma, lung 441 
cancer or colon cancer 15, 16, 48, 49. Growing evidence implicates GPCRs and their downstream 442 
signaling pathways in cancer pathology, especially angiogenesis 50. Since the GPCRs are 443 
excellent drug targets, a similar combinatorial strategy extending to different ligands of 444 
GPCRs involved in angiogenesis may identify novel therapeutic opportunities for cancer.  445  446 
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 615 
Figure Legends 616 
Figure 1: Aberrant growth of blood vessels in Hmga2/T tumors. 617 
(A and B) Representative sections of pituitary from WT (A) and pituitary tumors from 618 
Hmga2/T (B) mice immunostained with endomucin, a marker of blood vessels. Vascular 619 
density was lower in tumors and tumoral blood vessels were structurally altered, exhibiting 620 
dilation and strong tortuosity (arrows). Extravasation of red blood cells was present in tumors 621 
(double arrows). Scale bar: 50 µm. (C-G) Blood vessels visualized by SEM in pituitary 622 
sections from WT (C) and Hmga2/T mice (D-G). Vessels were enlarged and disorganized in 623 
tumors (D and F). Endothelial cells in tumor vessels overlapped one another with abnormal 624 
connections (E, arrows). (G) Higher magnification of F showing endothelial cells protruding 625 
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into the lumen (asterisk). Scale bar: 5 µm in C; 10 µm in D-G. (H-J) Ultrastructural 626 
visualization of blood vessels by transmission electron microscopy in pituitary from WT (H) 627 
and Hmga2/T mice (I and J). A capillary from normal pituitary, surrounded by endocrine 628 
cells, displayed a regular and smooth endothelium, a perivascular space with collagen fibers. 629 
By contrast, in tumors, vessels were large and disorganized. The endothelium was damaged, 630 
protrusions into the lumen were observed (arrows, I), and numerous red blood cells were 631 
present outside the vessels (asterisks, I and J). Scale bar: 5 µm in H-J. (K and L) In vivo 632 
imaging of pituitaries from WT (K) and Hmga2/T (L) mice after iv injection of fluorescent 633 
labeled-dextran. In WT, fluorescence was first detected in dural arteries from meninges 634 
surrounding the pituitary (arrows). Fluorescence was present in the adenohypophysis after 4 s 635 
and the whole pituitary vasculature was filled after 24 s. In Hmga2/T mice, in the tumoral 636 
region, the fluorescence was observed in vessels derived from dural arteries (arrowheads). 637 
Note that detection of fluorescence in the adenohypophysis through the portal system started 638 
at 21 s. Filling of the portal capillaries was complete after 1 min and 49 s.  Letters C and R 639 
indicate the caudal-rostral orientation of the animal. 640 
 641 
Figure 2: The direct arterial blood supply in tumors impedes the dopaminergic 642 
inhibitory tone without major hypothalamic dysfunction. 643 
(A) Dopaminergic inhibitory tone in WT and Hmga2/T mice at various stages. PRL blood 644 
concentrations were measured in basal conditions and after an injection of the D2R antagonist 645 
domperidone. The DA inhibitory tone (ratio between maximal and basal PRL secretion ± 646 
sem) was high in wild-type mice and during hyperplasia while tumors displayed a 647 
significantly lower tone. WT: n = 7; Hyperplasia: n = 7; Tumors 7-20 mg: n = 6; Tumors 648 
>20mg: n = 8. (B) Confocal images showing immunofluorescence labeling of hypothalamus 649 
sections from WT (left) and Hmga2/T mice (right) with TH (top) and phosphorylated TH 650 
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(pTH, bottom) antibodies. The staining obtained with TH or pTH antibody was similar in the 651 
arcuate nucleus and median eminence region in WT and Hmga2/T mice, showing that TIDA 652 
neurons were present and still produced DA in animals harboring tumors. Scale bar: 100 µm. 653 
(C) Amperometric measurements of DA secretion in the median eminence in vivo before the 654 
onset of tumors and during tumoral progression assessed by PRL concentration in blood.  655 
 656 
Figure 3: Bromocriptine prevents tumoral progression, aberrant vascular supply, and 657 
restores angiogenic balance. 658 
(A) Photographs of pituitary adenomas from Hmga2/T mice with (Bromocriptine 6 wks) and 659 
without (Tumor 6 wks) treatment with bromocriptine implants for 6 weeks, compared to 660 
pituitary tumor at the beginning of the treatment (Tumor t0). Scale bar: 2 mm. (B) Weight of 661 
pituitaries from Hmga2/T mice at the beginning of the treatment (Tumors t0, n = 6), or 662 
receiving or not (Tumors 6 wks, n = 6) bromocriptine for 6 weeks (Bromocriptine 6 wks, n = 663 
5). Tumoral progression was inhibited by bromocriptine. Kruskal-Wallis test followed by 664 
Dunn's multiple comparisons test, ** P<0.01. (C) Quantification of microspheres present in 665 
the adenohypophysis of Hmga2/T mice at the beginning of the treatment, or receiving or not 666 
bromocriptine for 6 weeks. The number of microspheres was significantly lower in 667 
bromocriptine-treated mice (n = 5) compared to untreated mice (n = 6). Kruskal-Wallis test 668 
followed by Dunn's multiple comparisons test, *** P<0.001. (D) Expression of pro- and anti-669 
angiogenic factors in tumoral Hmga2/T compared to WT mice. Angiogenic factor mRNA 670 
levels were quantified in Hmga2/T mice harboring pituitary tumors (n = 7) and WT of similar 671 
age (n = 5) by qPCR. Angiogenic profiles were altered in pituitary adenomas. Mann-Whitney 672 
test, * P<0.05, ** P<0.01. (E) Long-term effects of bromocriptine on angiogenic profiles in 673 
pituitary tumors. Angiogenic factor mRNA levels were quantified by qPCR in Hmga2/T mice 674 
harboring pituitary tumors and treated (n = 4) or not (n = 7) with implants of bromocriptine 675 
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for 6 weeks. Results are presented as ratio of gene expression in bromocriptine-treated tumors 676 
to untreated-tumors and show that bromocriptine restored the expression of angiogenic factors 677 
in tumors. Mann-Whitney test, * P<0.05, ** P<0.01. (F) Angpt1, Prok1 and Vegfa mRNA 678 
expression in pituitaries from Hmga2/T mice harboring tumors that received an acute 679 
treatment with bromocriptine (n = 5) or vehicle (n = 5). While Vegfa expression was not 680 
modified by bromocriptine, the D2R agonist increased Angpt1 and Prok1 mRNA levels. 681 
Mann-Whitney test, * P<0.05.  682 
 683 
Figure 4: Involvement of Vegf in the establishment of aberrant blood supply and tumor 684 
growth. 685 
 (A) Photographs of pituitary adenomas from Hmga2/T mice treated after tumor onset for 6 686 
weeks with vehicle or the anti-angiogenic agent axitinib. Axitinib-treated tumors appeared 687 
less hemorrhagic and tumor growth was reduced. (B) Weight of pituitaries from Hmga2/T 688 
mice receiving vehicle or axitinib for 6 weeks. Tumoral growth was decreased by axitinib. 689 
Mann Whitney test, ** P<0.01. (C) Quantification of microspheres present in the 690 
adenohypophysis from Hmga2/T mice receiving vehicle or axitinib for 6 weeks. The number 691 
of microspheres was significantly lower in axitinib-treated mice (n = 5) compared to vehicle-692 
treated mice (n = 6). Mann Whitney test, ** P<0.01. (D) Long-term effects of axitinib on 693 
angiogenic profiles in pituitary tumors. Angiogenic factor mRNA levels were quantified by 694 
qPCR in Hmga2/T mice harboring pituitary tumors and treated (n = 4) or not (n = 6) with 695 
axitinib for 6 weeks. Results are presented as ratio of gene expression in axitinib-treated 696 
tumors to untreated-tumors and show that axitinib did not restore the expression of Angpt1 697 
and Prok1 in tumors. Mann-Whitney test, * P<0.05, ** P<0.01. 698 
 699 
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Figure 5: Complementary effects of bromocriptine and axitinib on intratumoral 700 
hemorrhage. 701 
(A) Photographs of pituitary adenomas from Hmga2/T mice harboring untreated-tumors, or 702 
tumors treated for 6 weeks with either bromocriptine or axitinib, or combined bromocriptine 703 
and axitinib. (B) Paraffin embedded pituitary sections from WT mice, hyperplastic Hmga2/T 704 
mice, and Hmga2/T mice with pituitary tumors receiving various treatments for 6 weeks. 705 
Tissue sections were immunostained with endomucin, a marker of blood vessels. Scale bar: 706 
50 µm. Arrows: blood lakes. To better illustrate vascular density and defects, corresponding 707 
binary images obtained for quantification of blood vessel structural parameters are shown. (C) 708 
Ultra-structural visualization of pituitary blood vessels by TEM from WT and Hmga2/T mice 709 
exhibiting untreated-tumors, or tumors treated for 6 weeks with various therapies. Scale bar: 5 710 
µm. (D) Quantification of extravasation area in pituitary sections from WT and Hmga2/T 711 
mice receiving various treatments. Combination treatment with bromocriptine and axitinib 712 
almost totally abolished intratumoral hemorrhage.  n = 4 mice per condition.  Kruskal-Wallis 713 
test followed by Dunn's multiple comparisons test, * P<0.05, ** P<0.01, *** P<0.001. 714 
 715 
Figure 6: Restoration of blood vessel perfusion by bromocriptine and axitinib 716 
combination treatment. 717 
 (A) Blood vessel perfusion was assessed by intravenous injection of FITC-dextran in WT and 718 
Hmga2/T mice receiving various treatments. Pituitary sections were stained with endomucin 719 
(red) to visualize microvasculature. Poorly perfused blood vessels appeared in red and are 720 
particularly numerous in images obtained from untreated tumors. By contrast, the majority of 721 
blood vessels from tumors treated with both bromocriptine and axitinib exhibited green 722 
fluorescence. Scale bar: 200 µm. (B) Quantification of the overlap coefficient M1 reflecting 723 
the fraction of blood vessels filled with FITC-dextran in WT and Hmga2/T mice. 724 
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Combination treatment with bromocriptine and axitinib restored blood vessel perfusion, 725 
which was strongly impaired in untreated tumors, more effectively than each therapy alone. n 726 
= 4 mice per condition. Kruskal-Wallis test followed by Dunn's multiple comparisons test, 727 
*** P<0.001.  728 
 729 
 730 
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Figure 1: Aberrant growth of blood vessels in Hmga2/T tumors.  
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Figure 2: The direct arterial blood supply in tumors impedes the dopaminergic inhibitory tone without major 
hypothalamic dysfunction.  
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Figure 3: Bromocriptine prevents tumoral progression, aberrant vascular supply, and restores angiogenic 
balance.  
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Figure 4: Involvement of Vegf in the establishment of aberrant blood supply and tumor growth.  
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Figure 5: Complementary effects of bromocriptine and axitinib on intratumoral hemorrhage.  
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Figure 6: Restoration of blood vessel perfusion by bromocriptine and axitinib combination treatment.  
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